Recent Updates
Recently added Catalysts

No intervention; Observational study

Phase 3

Infection, Human Immunodeficiency Virus I | Small molecule | Infectious Disease |GSK plc|Last Updated: May 30, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment20

FDA Designations

No designations recorded

Clinical trial landscape

No intervention; Observational study · 1 trial · 2 indications

Phase 3 1
NCT00242840Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)Infection, Human Immunodeficiency Virus I
COMPLETED20 Analytics
PHASE3COMPLETED
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
Infection, Human Immunodeficiency Virus I
NCT0024284020
Unlock trial analytics

Study Design & Arms

Interventions

NameTypeDescription
No intervention; Observational studyDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range13 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites7

Inclusion criteria: * Prior participation in study APV30005 AND one of the following studies: APV30001, APV30002, AZL30006, APV30003. * Must be failing virologically (\>1000 copies at two consecutive time-points) and have a screening genotype with evidence of at least one new APV-associated proteas...

Countries:United StatesItaly
Unlock Eligibility Criteria